Diligence memo · auto-generated · as of July 2, 2026
Paradigm Diagnostics, Inc.
Paradigm Diagnostics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Paradigm Diagnostics, Inc. operates in Pharmaceuticals, based in PHOENIX.
Sub-sector tags: medical-devices.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Paradigm Diagnostics, Inc. has raised $11M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2016-11-16.
Most recent recorded round closed around 2016-11-16.
Valuation (modeled)modeled
Provath models Paradigm Diagnostics, Inc. at approximately $340M (range $13M–$1.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.91× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 9.6 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 56% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.